Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPHC.L Regulatory News (PHC)

  • There is currently no data for PHC

Trading Statement

22 Jan 2009 07:00

RNS Number : 0678M
Plant Health Care PLC
22 January 2009
 



For release: 7am 22 January 2009

 

PLANT HEALTH CARE PLC

("Plant Health Care" or "the Company")

Trading Update

Plant Health Care (AIM: PHC.L), a leading provider of natural products for plants and soil, provides the following post year end update for 2008, ahead of the announcement of its Preliminary Results which is expected by early April 2009.

The Company continues to trade well and, with further sales growth and the benefit of the initial order from Monsanto Company ("Monsanto") in the second half of the year, is expecting to report a result (before share based payments) in line with market expectations. 

The cash position at 31 December was $7.3 million, a marked improvement on the $6.2 million previously estimated, as a result of tight cash management.

In December 2008, Plant Health Care announced an agreement with Monsanto for the commercialisation of its harpin technology as a seed treatment in Monsanto's major row crops (corn, cotton, soybeans and canola) and selected vegetables. As stated above, a significant order has already been received and the board believes the Monsanto agreement will make a material contribution to the Company's future revenue and profits. It is expected that in future years the Monsanto payments will mainly fall into the second half of the year and this will accentuate the current trading pattern which sees stronger revenues in the second half, reflecting the timing of orders to suit the growing seasons.

Plant Health Care announced in December the termination of its agreement with Bayer CropScience for the development of Myconate. However, the Company is continuing its discussions with several large multinational seed companies and, supported by further strong test results for this product, expects to conclude an agreement with another party during 2009.

The Board considers that 2008 has seen significant progress for Plant Health Care, in particular the transformational agreement with Monsanto, and, despite challenging conditions in the wider economy, believes that the long term drivers of Plant Health Care's core markets remain very strong.

-Ends-

For further information please contact:

Plant Health Care plc

John Brady, Chief Executive Officer

Tel: +1-603-525-3702

jabrady@planthealthcare.com

 

Evolution Securities

Tavistock Communications 

Tim Worlledge / Tim Redfern

Jeremy Carey/Matt Ridsdale

Tel: +44-20-7071-4300 

Tel: +44-20-7920-3150

tim.worlledge@evosecuties.com/

tim.redfern@evosecuties.com

jcarey@tavistock.co.uk / mridsdale@tavistock.co.uk

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTIIFSRLVIFFIA
Date   Source Headline
28th Jun 202312:29 pmRNSHolding(s) in Company
27th Jun 20234:08 pmRNSHolding(s) in Company
27th Jun 20231:08 pmRNSDirector Shareholding
23rd Jun 20237:00 amRNSResult of Fundraising
22nd Jun 20234:35 pmRNSFundraising to raise up to US$3.6 million
14th Jun 20237:00 amRNSWilbur Ellis Agreement
13th Jun 20231:43 pmRNSResult of AGM
30th May 20237:00 amRNSHolding(s) in Company
24th May 20231:12 pmRNSHolding(s) in Company
19th May 20235:55 pmRNSPublication of Annual Report and Notice of AGM
18th May 20237:00 amRNSResult of Consultation
9th May 20237:00 amRNSPHC68949 granted first stage of approval in Brazil
2nd May 20237:10 amRNSResults for the year ended 31 December 2022
12th Apr 20232:33 pmRNSNotice of Results
5th Apr 20235:29 pmRNSHolding(s) in Company
8th Mar 20232:45 pmRNSExercise of Options
2nd Mar 20237:00 amRNSBiofungicide PHC279 Approved by US EPA
1st Mar 20237:00 amRNSDirector/PDMR Shareholding
6th Feb 20237:00 amRNSTrading Statement
30th Jan 202312:08 pmRNSSignificant Shareholder
18th Jan 20237:00 amRNSBoard Appointments
12th Jan 20237:00 amRNSNovozymes Distribution Agreement
9th Jan 20237:00 amRNSInvestor Presentation
22nd Dec 20227:00 amRNSNew Products Submitted for Regulatory Approval
28th Oct 20227:00 amRNSRegistration of Harpin in France
28th Oct 20227:00 amRNSNew distribution agreement with EDAF
27th Oct 20227:00 amRNSTrading Update
14th Oct 20225:11 pmRNSDirector/PDMR Shareholding
14th Oct 202210:39 amRNSDirector / PDMR Shareholding
26th Sep 20227:00 amRNSInterim Results
22nd Aug 20227:00 amRNSTrials agreement signed with Agrii UK
12th Aug 20227:00 amRNSGrant of Options
10th Aug 20225:04 pmRNSDirector/PDMR Shareholding
21st Jul 20222:41 pmRNSHolding(s) in Company
18th Jul 20227:02 amRNSInvestor Presentation
18th Jul 20227:00 amRNSPost-Close Trading Update
22nd Jun 202212:37 pmRNSResult of AGM
21st Jun 20227:00 amRNSCompletion of Nominated Adviser due diligence
20th Jun 20227:00 amRNSLong-term Harpin Production and Supply Agreement
6th Jun 20228:00 amRNSHolding(s) in Company
6th Jun 20228:00 amRNSHolding(s) in Company
1st Jun 20222:31 pmRNSDirector/PDMR Shareholding
25th May 20225:23 pmRNSHolding(s) in Company
23rd May 20227:30 amRNSAnnual Report & Accounts and Notice of AGM
23rd May 20227:00 amRNSNew distribution agreement with Nutrien
16th May 20227:00 amRNSHolding(s) in Company
12th May 20227:15 amRNSCEO appointment and Board changes
12th May 20227:00 amRNSResults for the year ended 31 December 2021
28th Apr 20227:00 amRNSChange of Adviser
21st Apr 20222:27 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.